Press coverage about Cepheid (NASDAQ:CPHD) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cepheid earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the scientific and technical instruments company an impact score of 46.6239992361452 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
The company has a quick ratio of 3.24, a current ratio of 4.30 and a debt-to-equity ratio of 0.76.
TRADEMARK VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/21/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-cepheid-cphd-share-price.html.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.